Nimocule Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-07-2024
- Paid Up Capital ₹ 0.10 M
as on 16-07-2024
- Company Age 18 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit -142.59%
(FY 2023)
- Ebitda -127.36%
(FY 2023)
- Net Worth -28.71%
(FY 2023)
- Total Assets -18.56%
(FY 2023)
About Nimocule Pharmaceuticals
The Corporate was formerly known as Rishom I T Softwares Pvt Ltd. The Company is engaged in the Information Technology Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Vijay Khurana, Naresh Sethi, and Pooja Gupta serve as directors at the Company.
- CIN/LLPIN
U85100DL2005PTC142690
- Company No.
142690
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Nov 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Nimocule Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijay Khurana  | Director | 18-Apr-2024 | Current |
| Pooja Gupta | Director | 12-Dec-2018 | Current |
| Naresh Sethi | Director | 12-Dec-2018 | Current |
Financial Performance and Corporate Structure Insights of Nimocule Pharmaceuticals.
Nimocule Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 142.59% decrease in profit. The company's net worth observed a substantial decline by a decrease of 28.71%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nimocule Pharmaceuticals?
In 2023, Nimocule Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Troge Scientific Research India Private Limited
Active 11 years 8 monthsVijay Khurana is a mutual person
Boulevard Projects Delhione Resident Welfare Association
Active 5 years 8 monthsVijay Khurana is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nimocule Pharmaceuticals?
Unlock and access historical data on people associated with Nimocule Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nimocule Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nimocule Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
